M. Funke-Chambour (Bern, Switzerland), C. Valenzuela (Madrid, Spain)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
A novel prognostic signature based on five-immune-related genes for idiopathic pulmonary fibrosis
L. Qiu (Zhengzhou, China), G. Gong (Guangzhou, China), G. Zhang (Zhengzhou, China)
|    |
Clinical course of suspected familial versus sporadic IPFData from the PROOF-Next IPF registry
A. Froidure (Bruxelles, Belgium), B. Bondue (Bruxelles, Belgium), C. Dahlqvist (Yvoir, Belgium), J. Guiot (Liège, Belgium), N. Gusbin (Liège, Belgium), G. Wirtz (Luxembourg, Luxembourg), G. Joos (Gent, Belgium), D. Strens (Leuven, Belgium), H. Slabbynck (Antwerpen, Belgium), W. Wuyts (Leuven, Belgium)
| |
Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD)
D. Dos Reis Estrella ( Belo Horizonte (MG), Brazil), F. Sacilotto Donaires (Ribeirão Preto (SP), Brazil), A. Pinto Santos (Ribeirão Preto (SP), Brazil), E. Viana Mancuzo (Belo Horizonte (MG), Brazil), R. Tocantins Calado (Ribeirão Preto (SP), Brazil), R. De Amorim Corrêa (Belo Horizonte (MG), Brazil)
| |
Pulmonary fibrosis in non-mutation carriers of families with short telomere syndrome gene mutations.
A. van der Vis (Nieuwegein, Netherlands), J. Van Der Smagt (Utrecht, Netherlands), A. Van Batenburg (Nieuwegein, Netherlands), W. Van Es (Nieuwegein, Netherlands), J. Grutters (Nieuwegein, Netherlands), C. Van Moorsel (Nieuwegein, Netherlands)
| |
Bioinformatics analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis
N. Li (Zhengzhou, China), L. Qiu (Zhengzhou, China), C. Zeng (Zhengzhou, China), G. Zhang (Zhengzhou, China)
| |
Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients
T. Cruz (Barcelona, Spain), A. Bondonese (Pittsburgh, United States of America), J. Sembrat (Pittsburgh, United States of America), T. Tabib (Pittsburgh, United States of America), W. Zhang (Pittsburgh, United States of America), N. Mitash (Pittsburgh, United States of America), D. Vignali (Pittsburgh, United States of America), A. Mora (Columbus, United States of America), R. Lafyatis (Pittsburgh, United States of America), M. Rojas (Columbus, United States of America)
| |
Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF
D. Kalafatis (Stockholm, Sweden), A. Löfdahl (Lund, Sweden), P. Näsman (Stockholm, Sweden), L. Elowsson Rendin (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden), M. Sköld (Stockholm, Sweden)
| |
Biosynthesis and implementation of Thyroid Receptor beta (TRß) agonists (thyromimetics) for the treatment of pulmonary fibrosis
A. Matralis (Athens, Greece), T. Karampitsakos (Patras, Greece), O. Papaioannou (Patras, Greece), M. Katsaras (Patras, Greece), F. Sampsonas (Patras, Greece), D. Bouros (Athens, Greece), V. Aidinis (Athens, Greece), A. Tzouvelekis (Patras, Greece)
| |
LSC - 2021 - The Anti-Fibrotic Drug Nintedanib Promotes Repair Macrophages
K. Carolin, K. Fundel-Clemens, D. Schlösser, C. Lerner, S. Frey, C. T. Wohnhaas, C. Viollet, S. Dichtl, C. Tilp , M. J. Thomas, F. Gantner, W. Skronska-Wasek, H. J. Huber, P. J. Murray, F. Ramirez, K. C. El Kasmi
| |
Late Breaking Abstract - Prevalence of interstitial lung abnormalities in a Swedish population-based sample
I. Pesonen (Stockholm, Sweden), Å. Johnsson (Gothenburg, Sweden), F. Johansson (Stockholm, Sweden), P. Wollmer (Linköping, Sweden), E. Lindberg (Uppsala, Sweden), A. Blomberg (Umeå, Sweden), K. Torén (Gothenburg, Sweden), C. Östgren (Linköping, Sweden), M. Sköld (Stockholm, Sweden)
| |
Discussion
| |